Compare Toronto-Dominion Bank (TD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs TG Therapeutics Inc — how do they compare? Toronto-Dominion Bank trades at $120.5 (market cap $197.03B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Toronto-Dominion Bank is far larger — about 23.9× TG Therapeutics Inc's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TD | TGTX | |
|---|---|---|
Market Cap | $197.03B | $8.26B |
Sector | Financials | Health |
52-Week High | $124.80 | $59.06 |
52-Week Low | $72.55 | $26.39 |
Dividend Yield | 2.62% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
